Literature DB >> 7678996

Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro.

E F Srour1, J E Brandt, R A Briddell, S Grigsby, T Leemhuis, R Hoffman.   

Abstract

Although sustained production of committed human hematopoietic progenitor cells in long-term bone marrow cultures (LTBMC) is well documented, evidence for the generation and expansion of human primitive hematopoietic progenitor cells (PHPC) in such cultures is lacking. For that purpose, we attempted to determine if the human high proliferative potential colony-forming cell (HPP-CFC), a primitive hematopoietic marrow progenitor cell, is capable of generation and expansion in vitro. To that effect, stromal cell-free LTBMC were initiated with CD34+ HLA-DR-CD15- rhodamine 123dull bone marrow cells and were maintained with repeated addition of c-kit ligand and a synthetic interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein. By day 21 of LTBMC, a greater than twofold increase in the number of assayable HPP-CFC was detected. Furthermore, the production of HPP-CFC in LTBMC continued for up to 4 weeks, resulting in a 5.5-fold increase in HPP-CFC numbers. Weekly phenotypic analyses of cells harvested from LTBMC showed that the number of CD34+ HLA-DR- cells increased from 10(4) on day 0 to 56 CD34+ HLA-DR- cells increased from 10(4) on day 0 to 56 x 10(4) by day 21. To examine further the nature of the in vitro HPP-CFC expansion, individual HPP-CFC colonies were serially cloned. Secondary cloning of individual, day 28 primary HPP-CFC indicated that 46% of these colonies formed an average of nine secondary colony-forming unit--granulocyte-macrophage (CFU-GM)--derived colonies, whereas 43% of primary HPP-CFC gave rise to between one and six secondary HPP-CFC colonies and 6 to 26 CFU-GM. These data show that CD34+ HLA-DR- CD15- rhodamine 123dull cells represent a fraction of human bone marrow highly enriched for HPP-CFC and that based on their regeneration and proliferative capacities, a hierarchy of HPP-CFC exists. Furthermore, these studies indicate that in the presence of appropriate cytokine stimulation, it is possible to expand the number of PHPC in vitro.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678996

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Peripheral blood stem cells: phenotypic diversity and potential clinical applications.

Authors:  Yichi Zhang; Bing Huang
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

Review 2.  Optimizing the effectiveness of hematopoietic growth factors.

Authors:  D E Williams
Journal:  J Clin Immunol       Date:  1994-07       Impact factor: 8.317

3.  Proliferation of human hematopoietic bone marrow cells in simulated microgravity.

Authors:  P A Plett; S M Frankovitz; R Abonour; C M Orschell-Traycoff
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-02       Impact factor: 2.416

4.  Clonal analysis and hierarchy of human bone marrow mesenchymal stem and progenitor cells.

Authors:  C Chang I Lee; Jared E Christensen; Mervin C Yoder; Alice F Tarantal
Journal:  Exp Hematol       Date:  2010-01       Impact factor: 3.084

5.  Long-term repopulating ability of xenogeneic transplanted human fetal liver hematopoietic stem cells in sheep.

Authors:  E D Zanjani; A W Flake; H Rice; M Hedrick; M Tavassoli
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

6.  Transdifferentiation of Human Hair Follicle Mesenchymal Stem Cells into Red Blood Cells by OCT4.

Authors:  Zhijing Liu; Shi-Jiang Lu; Yan Lu; Xiaohua Tan; Xiaowei Zhang; Minlan Yang; Fuming Zhang; Yulin Li; Chengshi Quan
Journal:  Stem Cells Int       Date:  2015-02-09       Impact factor: 5.443

7.  The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit.

Authors:  H K Habibian; S O Peters; C C Hsieh; J Wuu; K Vergilis; C I Grimaldi; J Reilly; J E Carlson; A E Frimberger; F M Stewart; P J Quesenberry
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.